Kytes positions itself as a project management software built for pharmaceutical realities—not generic project tracking. It supports regulatory execution, dossier readiness, country-wise launch ...

Q4 2025 earnings call: record bookings, project delays, 2026 revenue/EBITDA outlook, margins and risks—read now.

Guidance language remained steady, with a continued 9% EBITDA growth target for 2026 and flattish volume outlook, consistent with the previous quarter. Strategic focus expanded on innovation (notably ...

The California Capitol Annex overhaul is entering its most expensive phase as lawmakers quietly shift leadership while ...

Sun Pharmaceutical will invest Rs 500 crore to establish a new manufacturing plant in Assam. This significant project will ...

Renewables remain resilient in 2026 as developers adapt to market risks with solar + storage growth, wind repowering, and ...

Northland’s Taiwan offshore wind ramp is the make-or-break story for 2026, and delays are already reshaping cash flow ...

Industrials products and automation company Regal Rexnord (NYSE:RRX). in Q4 CY2025 as sales rose 4.3% year on year to $1.52 ...

Real estate and infrastructure players cite the positive impact of RBI repo rate pause at 5.25% in terms of EMI stability and borrowing-cost clarity.. Industry opinion divided on RBI repo rate pause.

Xavantina's mining and processing operations are projected to deliver higher sustained production of between 50,000 and ...

Israel’s economy has demonstrated notable resilience. Following the Gaza ceasefire, economic activity accelerated markedly, ...